Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00828
|
|||||
| Drug Name |
Cefoxitin
|
|||||
| Synonyms |
cefoxitin; Mefoxin; Cefoxitine; Cefoxitinum; Cefoxitina; CEPHOXITIN; Mefoxitin; Rephoxitin; UNII-6OEV9DX57Y; CHEMBL996; 6OEV9DX57Y; CFX; AK118716; DSSTox_CID_2764; DSSTox_RID_76721; DSSTox_GSID_22764; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[(aminocarbonyl)oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-, (6R,7S)-; CAS-35607-66-0; NCGC00183034-01; ceftoxitin; Cefoxotin; 4kow
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Bacterial infections [ICD11: 1A00-1H0Z] | Approved | [1] | |||
| Therapeutic Class |
Antibiotics
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C16H17N3O7S2
|
|||||
| Canonical SMILES |
COC1(C2N(C1=O)C(=C(CS2)COC(=O)N)C(=O)O)NC(=O)CC3=CC=CS3
|
|||||
| InChI |
InChI=1S/C16H17N3O7S2/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22)/t14-,16+/m1/s1
|
|||||
| InChIKey |
WZOZEZRFJCJXNZ-ZBFHGGJFSA-N
|
|||||
| CAS Number |
CAS 35607-66-0
|
|||||
| Pharmaceutical Properties | Molecular Weight | 427.5 | Topological Polar Surface Area | 202 | ||
| Heavy Atom Count | 28 | Rotatable Bond Count | 8 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 9 | |||
| XLogP |
0
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:209807
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | PEPT1 | Transporter Info | Peptide transporter 1 | Substrate | [2] | |
| References | ||||||
| 1 | Cefoxitin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.